key: cord-0977755-ywl11fbg
authors: Maynard, Suzanne; Ros-Soto, Jose; Chaidos, Aris; Innes, Andrew; Paleja, Krushika; Mirvis, Eitan; Buti, Noora; Sharp, Harriet; Palanicawandar, Renuka; Milojkovic, Dragana
title: The role of ibrutinib in COVID-19 hyperinflammation: a case report
date: 2021-02-16
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.02.056
sha: 189cbe868ec92b20c40d7fb1127846d7db1825bc
doc_id: 977755
cord_uid: ywl11fbg

nan

inflammatory cytokines and lessen acute lung injury (Florence et al. 2018) , this could be applicable in the context of hospitalised COVID-19 patients (Thibaud et al. 2020; Treon et al. 2020; Woyach, 2020) . Patients already on treatment with BTKis may be at high risk of infection with poor outcomes given advanced age, comorbidities and immune dysfunction. However, a recent multicenter analysis did not show any negative impact on survival of patients with chronic lymphocytic leukaemia hospitalised due to COVID-19 infection whilst receiving a BTKi (Mato et al. 2020) . We report the outcome of an ibrutinib treated patient with COVID-19 who suffered respiratory deterioration after ibrutinib cessation, and promptly improved after ibrutinib re-introduction.

We describe an 81 year-old male receiving ibrutinib for Waldenstrom macroglobulinaemia (WM) who was hospitalised with COVID-19. WM is a relatively indolent lymphoproliferative disorder characterized by IgM monoclonal gammopathy and lymphoplasmacytic infiltrate in the bone marrow. On stopping the BTKi due to concerns of additional immunosuppression, he required non-invasive ventilation (NIV) in the intensive care unit (ICU) and demonstrated prompt clinical recovery when ibrutinib was reinstated.

On admission, the patient described a one-week history of nausea, fever and dry cough with c-reactive protein (CRP) 73.4mg/l and was commenced on intravenous (IV) piperacillin-tazobactam. COVID swab RT-PCR at admission was positive. His observations were stable, he did not require additional oxygen and blood tests and chest x-ray (CXR) were unremarkable. Five days later, 11 days since symptoms onset, he became pyrexial at 38 o C, CRP had increased to 136mg/l and he was commenced on oral azithromycin and once daily dexamethasone 8mg. Repeat CXR showed new pulmonary opacities but he remained clinically stable with no oxygen requirement. Ibrutinib was withheld from day 6 of admission. CRP improved to 76 mg/L in accordance with the introduction of steroids (Markanday , 2015) . Forty-four hours following the last dose of BTKi he developed a new, rapidly increasing, oxygen requirement and within 8 hours he was admitted to ICU for NIV to achieve adequate oxygenation (day 7 of admission, 13 days since symptoms onset) (see figure A) .

Within 24 hours of ITU admission, his BTKi was reinstated at full dose 420mg and remdesivir was commenced. A brief rise and subsequent fall in CRP was observed to follow the pattern of events (see figure A) . After only 14 hours of NIV (initial requirements of PEEP 8 and FiO2 55) his oxygen requirements decreased and the following day he was stepped down to the ward on 4L O2 via nasal cannula. He continued to improve and at 19 days after admission (day 25 of symptoms onset) he was medically fit for discharge with no supplementary oxygen requirement. Consideration should be given to the potential contribution on symptoms of the known 'ibrutinib withdrawal' phenomena which typically occurs within 5 days following treatment cessation. However, documented symptoms of 'Ibrutinib withdrawal' include fever, generalised aches, headache and arthralgia which were absent here. Furthermore, increased oxygen requirement has not been described within the withdrawal symptoms (Castillo et al. 2017) . 

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

Ibrutinib withdrawal symptoms in patients with Waldenstrom macroglobulinemia

Covid-19: Remdesivir has little or no impact on survival, WHO trial shows

Inhibiting Bruton's tyrosine kinase rescues mice from lethal influenza-induced acute lung injury

Acute Phase Reactants in Infections: Evidence -Based Review and a Guide for Clinicians

Outcomes of COVID-19 in patients with CLL: a multicenter international experience

COVID-19: consider cytokine storm syndromes and immunosuppression

Remdesivir for severe covid-19: a clinical practice guideline

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19